Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes

American Journal of Clinical Pathology

Volumn 138, Issue 5, 2012, Pages 732-743

  De Smet, Dieter ^a   Trullemans, Fabienne ^a   Jochmans, Kristin ^a   Renmans, Wim ^a   Smet, Lut ^a   Heylen, Olivier ^a   Bael, Anne Mie ^a   Schots, Rik ^a   Leus, Barbara ^a   De Waele, Marc ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Acute myeloid leukemia; Antigen expression; Bone marrow; CD34+ cells; Flow cytometry; Myelodysplastic syndromes

Indexed keywords

B LYMPHOCYTE ANTIGEN; CD123 ANTIGEN; CD133 ANTIGEN; CD19 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CELL ANTIGEN; CHEMOKINE RECEPTOR CXCR4; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; MICROSOMAL AMINOPEPTIDASE; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CD34 SELECTION; CONTROLLED STUDY; CYTOPENIA; DIAGNOSTIC VALUE; DYSPLASIA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PRIORITY JOURNAL;

ADULT; ANTIGENS, CD34; BONE MARROW; BONE MARROW CELLS; HUMANS; IMMUNOPHENOTYPING; MYELODYSPLASTIC SYNDROMES;

EID: 84868106325     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPAGVO27RPTOTV     Document Type: Article

References (31)

1. Mufti GJ, Galton DA. Myelodysplastic syndromes: natural history and features of prognostic importance. Clin Haematol. 1986;15:953-971.
2. Yoshida Y, Stephenson J, Mufti GJ. Myelodysplastic syndromes: from morphology to molecular biology, I: classification, natural history and cell biology of myelodysplasia. Int J Hematol. 1993;57:87-97. (Pubitemid 23132622)
3. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
4. Ogata K, Yoshida Y. Clinical implications of blast immunophenotypes in myelodysplastic syndromes. Leuk Lymphoma. 2005;46:1269-1274. (Pubitemid 41269292)
5. Ogata K, Kishikawa Y, Satoh C, et al. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood. 2006;108:1037-1044. (Pubitemid 44154642)
6. Matarraz S, López A, Barrena S, et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia. 2008;22:1175-1183. (Pubitemid 351833785)
7. Ogata K. Diagnostic flow cytometry for low-grade myelodysplastic syndromes. Hematol Oncol. 2008;26:193-198.
8. Harrington A, Olteanu H, Kroft S. The specificity of immunophenotypic alterations in blasts in nonacute myeloid disorders. Am J Clin Pathol. 2010;134:749-761.
9. van de Loosdrecht AA, Westers TM, Westra AH, et al. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood. 2008;111:1067-1077. (Pubitemid 351213384)
10. Ogata K, Nakamura K, Yokose N, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood. 2002;100:3887-3896. (Pubitemid 35396853)
11. Consuelo del Canizo M, Fernandez E, Lopez A, et al. Immunophenotypic analysis of myelodysplastic syndromes. Haematologica. 2003;88:402-407. (Pubitemid 36547126)
12. Pirruccello SJ, Young KH, Aoun P. Myeloblast phenotypic changes in myelodysplasia: CD34 and CD117 expression abnormalities are common. Am J Clin Pathol. 2006;125:884-894. (Pubitemid 43801539)
13. Goardon N, Nikolousis E, Sternberg A, et al. Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes. Haematologica. 2009;94:1160-1163.
14. Malcovati L, Della Porta MG, Lunghi M, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2005;19:776-783. (Pubitemid 40663097)
15. Matarraz S, López A, Barrena S, et al. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom. 2010;78:154-168.
16. Xu F, Li X, Wu L, et al. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes. Br J Haematol. 2010;149:587-597.
17. Falco P, Levis A, Stacchini A, et al. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes. Eur J Haematol. 2011;87:409-418.
18. De Waele M, Renmans W, Vander Gucht K, et al. Growth factor receptor profile of CD34+ cells in AML and B-lineage ALL and in their normal bone marrow counterparts. Eur J Haematol. 2001;66:178-187. (Pubitemid 32324584)
19. Testa U, Riccioni R, Militi S, et al. Elevated expression of IL-3R alpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100:2980-2988.
20. Van Rhenen A, Moshaver B, Ossenkoppele GJ, et al. Aberrant marker expression patterns on the CD34+CD38-stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia. 2007;21:1700-1707. (Pubitemid 47086760)
21. Wei X, Wang X, Du W, et al. Detection of molecular targets on the surface of CD34+CD38- bone marrow cells in myelodysplastic syndromes. Cytometry A. 2010;77:840-848.
22. Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother. 2007;30:607-613. (Pubitemid 47229695)
23. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90:5002-5012. (Pubitemid 28007217)
24. Wuchter C, Ratei R, Spahn G, et al. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. Haematologica. 2001;86:154-161. (Pubitemid 32216088)
25. Kussick SJ, Fromm JR, Rossini A, et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol. 2005;124:170-181. (Pubitemid 41060126)
26. Möhle R, Bautz F, Rafii S, et al. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood. 1998;91:4523-4530. (Pubitemid 28270300)
27. Ishii T, Nishihara M, Ma F, et al. Expression of stromal cell-derived factor-1/pre-B cell growth-stimulating factor receptor, CXC chemokine receptor 4, on CD34+ human bone marrow cells is a phenotypic alteration for committed lymphoid progenitors. J Immunol. 1999;163:3612-3620. (Pubitemid 29450881)
28. Möhle R, Schittenhelm M, Failenschmid C, et al. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol. 2000;110:563-572.
29. Kim HK, De La Luz Sierra M, Williams CK, et al. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood. 2006;108:812-820. (Pubitemid 44154612)
30. Truong F, Smith BR, Stachurski D, et al. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study. Leuk Res. 2009;33:1039-1046.
31. Yue LZ, Wang HQ, Li LJ, et al. Expression of CD123 and CD114 on the bone marrow cells of patients with myelodysplastic syndrome. Chin Med J. 2010;123:2034-2037.